Mettler-Toledo International Overview
Valuation check: MTD's ROE is -20.89%, below the Healthcare sector average of 29.39%.
Get informed when a big investor buys or sells
+ Follow-2089.30%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for MTD is -20.89%. That is below the Healthcare sector average of 29.39%. Investors often review this figure alongside Mettler-Toledo International's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, MTD currently prints -20.89% for ROE, while the sector average sits near 29.39%. That is roughly 7208.8% below the sector mean. Large gaps often invite a closer look at Mettler-Toledo International's growth, margins, and balance sheet.
Return on Equity shows how effectively Mettler-Toledo International converts resources into returns. At -20.89%, MTD may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting MTD's ROE (-20.89%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Mettler-Toledo International's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
